Seeking Alpha

Seeking Alpha Portfolio App for iPad

531 people get SUPN articles and Market Currents by email alert.

Get email alerts on SUPN »

SUPN

Supernus Pharmaceuticals, Inc.

6/19/2013, 6:59 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 4:07 PM Supernus Pharmaceuticals (SUPN): Q1 EPS of -$0.60 beats by $0.11. Revenue of $147K misses by $423K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, April 26, 11:53 AM Supernus Pharmaceuticals (SUPN +10.6%) moves up after pricing its $75M offering of convertible senior secured notes due 2019. The company intends to use approximately $21M million of the net proceeds to repay in full its borrowings under and terminate its secured credit facility and the remainder of the net proceeds to fund the commercialization of its approved and tentatively approved drugs, Oxtellar XR and Trokendi XR, and to continue development of its pipeline. Comment! [Healthcare, On the Move]
Wednesday, April 24, 6:03 PM Supernus Pharmaceuticals (SUPN) announces a private offering of $75M in Convertible Senior Notes due 2019, with a 30-day option to purchase up to an additional $15M. The notes are being secured by liens on substantially all of SUPN's assets. Shares -14% AH. Comment! [Healthcare, On the Move]
Wednesday, April 24, 5:52 PM After-hours top gainers, as of 5:15 p.m.: AKAM +16%. FIO +12%. AVG +10%. ANGI +8%. BYI +6%.
After-hours top losers: SUPN -14%. CTXS -12%. EQIX -11%. INTU -10%. ZNGA -8%. Comment! [On the Move]
Tuesday, March 26, 5:45 PM After-hours top gainers, as of 5:15 p.m.: MXWL +9%. SAI +4%. OWW +3%. SPLK +3%. SUPN +3%.
After-hours top losers: LNDC -8%. ACMP -4%. EOG -4%. PXD -3%. LOGM -3%. 1 Comment [On the Move]
Thursday, March 14, 4:57 PM Supernus Pharmaceuticals (SUPN): Q4 EPS of -$0.51 beats by $0.20. Revenue of $1.09M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Friday, November 30, 2012, 1:04 PM Midday top 10 gainers: MARK +38%. MITL +30%. MHH +25%. CBK +24%. PPHM +24%. AMPL +24%. TELK +19%. PLNR +17%. TLAB +15%. FIVE +15%.
Top 10 Losers: RIC -24%. NTLS -23%. FFKY -19%. SUPN -18%. SBLK -14%. VRSN -14%. PSUN -14%. MMYT -13%. HGSH -13%. PWX -11%. Comment! [On the Move]
Friday, November 30, 2012, 7:45 AM Supernus Pharmaceuticals (SUPN) dives 16% after pricing a 6M secondary at just $8/share. The stock was trading at $11 late yesterday afternoon. (PR) Comment! [Healthcare, On the Move]
Monday, October 22, 2012, 1:38 PM Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age. Comment! [Healthcare]
Monday, October 22, 2012, 9:10 AM Premarket gainers: PGRX +42%. SUPN +16%. SVU +7%. ACOM +8%. OREX +7%. NBG +6%. BTU +6%. PHG +6%. GIVN +6%.
Losers: OSG -50%. NXY -7%. Comment! [On the Move]
Wednesday, June 27, 2012, 9:05 AM Premarket gainers: ENTR +25%. AMRN +15%. SUPN +8%. WPRT +8%.
Losers: ORLY -17%. OMER -16%. CCG -6%. Comment! [On the Move]
Tuesday, June 26, 2012, 9:10 AM Premarket gainers: SUPN +38%. SCMF +12%. NWSA +7%. APOL +6%.
Losers: JRCC -8%. LDK -7%. Comment! [On the Move]
Tuesday, June 26, 2012, 8:28 AM Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR. Comment! [Healthcare, On the Move]